Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of APL-1501 ER vs APL-1202 IR in Healthy Volunteers
NCT06435039Phase 1Terminated
- Sponsor
- Syneos Health
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of APL-1202 + APL-1501 in bladder cancer (5 cohorts), sponsored by Syneos Health. Primary endpoints: Number of Participants With Adverse Events (AEs) at Day 9, Number of Participants With Abnormal Vital Sign Measurements at Day 9 and 3 more. Started Jun 2024; status: terminated.
02
Drugs
APL-1202 + APL-1501
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06435039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435039.